Bluejay Investor Presentation Deck

Symphony IL-6 Regulatory Timeline for Sepsis to Reach Commercialization ●●● ●● Q4 '21 Initial clinical trials bluejay DIAGNOSTICS Q2 '22 FDA feedback; including de novo designation Q1 '22 Filed FDA pre-submission Q4 '22 Filed pre-submission supplement with FDA Q3 '22 Completed initial clinical trials Q1 '23 FDA feedback; study expansion required Q4 '22 Expanded trials to support de novo submission H1 24 Planned 510(k) FDA submission Q2 '23 Modify trial inclusion to obtain more patient data 2025 Planned commercialization H2 '24 Planned 510(k) FDA submission response We estimate there will be an incremental capital need of about $15 million to get through FDA approval Copyright ©2023 Bluejay Diagnostics, Inc. All rights reserved in all slides | November 2023 12

View entire presentation